Hypercholesterolemia
838
21
33
670
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
198 trials with published results (24%)
Research Maturity
670 completed trials (80% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
5.1%
43 terminated out of 838 trials
94.0%
+7.5% vs benchmark
37%
307 trials in Phase 3/4
30%
198 of 670 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 670 completed trials
Clinical Trials (838)
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
Pharmacokinetics of Butyrate Tablet BKR-017
Causes and Natural History of Dyslipidemias
A Post-Marketing Clinical Trial of Pemafibrate in Patients with Hypercholesterolemia and Inadequate Response to Statins
Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
Pravastatin and Protease Inhibitors in HIV-infected Patients
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.
Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD
Improving Lipid Optimization Quality and Treatment Options in ASCVD
WB-EMS Effects on Cardiometabolic Risk Factors
Study on the Effect of the Intake of a Calcium-bicarbonate Water on Cholesterol Levels
Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol
Vascular Intervention Strategies Trial for Alzheimer's
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Assessing the Effects of Corn and Avocado Oils on the Cardiometabolic Risk Factor Profile
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
Dachundou No Sugar Added Soymilk for Lipid Modulation